Swipe Left For English News
1
EffiXTM旨在满足市场对高产、稳定、非溶源性的大肠杆菌（E. coli）表达系统的需求，为全球客户研发和生产非单抗类重组蛋白和质粒DNA提供全面解决方案
2
EffiXTM可在多种不同类型的分子中实现高产量，其中非单抗重组蛋白产量超过15克/升，质粒DNA产量超过1克/升
杭州
2025年3月4日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）今日宣布推出创新技术平台EffiXTM。该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA。
随着抗体片段、纳米抗体、酶、细胞因子、各种抗原、多肽及质粒DNA（pDNA）等分子量更小的复杂生物分子市场需求迅速增长，基于微生物表达系统的生物制品及其中间体的市场规模在全球范围内不断扩大，这也为新一代疗法的开发带来了新机遇。为了解决生产这些分子所面临的挑战，药明生物打造了EffiXTM，赋能高产量、高质量、高稳定性和高拓展性的微生物衍生生物制品的研发和生产。在该平台的助力下，非单抗重组蛋白产量超过15克/升，质粒DNA产量超过1克/升。
EffiXTM平台通过提供全面且具有成本效益的CMC策略，简化工艺开发流程，可以满足从研究到商业化生产的各种项目服务需求，助力全球合作伙伴加速研发创新生物疗法。
陈智胜
博士
药明生物首席执行官
我们很高兴推出创新技术平台EffiXTM，升级微生物解决方案。无论产品处于任何开发阶段，该平台都能够在保证产品质量的前提下，提供出色的产量、可扩展性及灵活性。药明生物长期以来不断推陈出新，持续建立先进技术平台，突破业界技术瓶颈，这一切都是为了更好地赋能全球合作伙伴，让全球患者更快地用得到、用得起更多高质量生物药。
药明生物基于微生物表达系统，包括EffiXTM在内，全面建立了一体化技术平台。该平台涵盖了早期研究、CMC开发和GMP生产，为新一代疗法提供更快、更高效和更具成本效益的解决方案。
关于药明生物
药明生物（代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
业务垂询
info@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Launches EffiXTM Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
1
EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe.
2
EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
HANGZHOU
March 4, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of its innovative technology platform, EffiX™, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA.
The global market for microbial-derived products and intermediates is expanding rapidly, driven by increasing demand for smaller complex biomolecules — such as antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA (pDNA) — all of which present significant opportunities for the development of next-generation therapies. To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with high yield, consistent quality, as well as superior stability and scalability. The EffiX™ platform achieves titers exceeding 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.
With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative biotherapeutics for global partners by offering a comprehensive and cost-effective Chemistry, Manufacturing, and Controls (CMC) strategy.
Dr. Chris Chen
Chief Executive Officer
WuXi Biologics
We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development. WuXi Biologics' continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide.
The EffiX™ platform is an integral component of a broader integrated technology platform at WuXi Biologics, which is predicated on microbial expression systems. This comprehensive platform encompasses early-stage research, CMC development, and GMP manufacturing, facilitating faster, more efficient, and cost-effective manufacturing processes for various modalities in the realm of next-generation therapies.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间接收药明生物最新动态
2025-06-15
26页
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论